จะมาวันไหน

จะมาวันไหน

ผลลัพธ์ (อังกฤษ) 1:

When will you come

ผลลัพธ์ (อังกฤษ) 2:

heterogeneous disease and the etiology is still unclear. Early detection and early treatment can
increase survival. However, metastasis to other tissues occurs in a large number of patients,
especially in triple-negative (TN) breast cancer [2]. More than 90% of breast cancer deaths are
due to metastasis-related complications [3]. Breast cancer cells can metastasize to diverse

organs including lung, liver, bone, brain, etc., and once resident can proliferate into macro-
scopic masses, leading ultimately to death [4]. Five-year survival rates for distant metastasis

breast cancer patients are less than 20% [5].

Metastasis is frequently a final and fatal step in the progression of solid tumors. The meta-
static process consists of tumor cell intravasation, survival in circulation, extravasation into a

distant organ, angiogenesis and uninhibited growth [6]. When cancer cells metastasize to

other distant organs, microenvironmental factors work to overcome many barriers. In particu-
lar, when breast cancer cells metastasize from primary tumors to specific tissues, communica-
tion between the disseminated tumor cells and the resident stromal cells in those colonized

tissues is varied but thought to be important to tumor progression. There are a variety of com-
ponents that make up the microenvironment of tumors such as growth factors, immune cells,

cytokines, chemokines, extracellular matrix (ECM), tumor-associated macrophages, and can-
cer-associated fibroblasts [7].

The mechanisms that determine which organs become metastasized by breast cancer are
complex and influenced by many factors. One of them is the molecular subtype. Breast cancer
is subdivided into four major clinical subtypes based on gene expression profiles and receptor
status (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor
receptor 2 (HER2) and proliferative status as assessed by Ki67 [8]. These clinical subtypes can

be classified as luminal A (ER +/PR +), luminal B (ER +/PR +/HER2-/+/Ki67 +), HER2 over-
expression (ER-/PR-/HER +) and basal-like/TN (ER-/PR-/HER2-). Bone is the most common

site of metastasis in all subtypes, but TN breast cancer is most likely to metastasize to the lung
[9]. However, the timing and mechanism by which breast cancer molecular subtypes can affect
metastasis to the lung are still unknown. Endeavors to understand the molecular mechanisms

that induce breast cancer metastasis in the lung and to incorporate it into new therapies con-
tinue [10].

Recently, there is active interest in using products of natural medicinal plants that have
anticancer effects and do not have cytotoxic values for cancer therapy or to overcome cancer

cell drug resistance. Among these, taxol analogues, vinca alkaloids, and podophyllotoxin ana-
logues play an important role in the treatment of some cancer patients [11]. Toxicodendron

vernicifluum (formerly Rhus verniciflua) Stokes belongs to the Anacardiaceae family and is
commonly known as th

ผลลัพธ์ (อังกฤษ) 3:

Which day?